Edition:
United Kingdom

Pharmaceuticals

Page 1

Conatus Says Top-Line Results From Encore-LF Clinical Trial Of Emricasan Did Not Meet Primary Endpoint

Monday, 24 Jun 2019

June 24 (Reuters) - Conatus Pharmaceuticals Inc ::CONATUS ANNOUNCES RESULTS FROM ENCORE-LF AND ENCORE-PH PHASE 2B CLINICAL TRIALS IN NASH CIRRHOSIS.CONATUS PHARMACEUTICALS INC - TOP-LINE RESULTS FROM COMPANY'S ENCORE-LF CLINICAL TRIAL OF EMRICASAN DID NOT MEET ITS PRIMARY ENDPOINT.CONATUS PHARMACEUTICALS INC - DISCONTINUING FURTHER TREATMENT OF PATIENTS ENROLLED IN ENCORE-LF CLINICAL TRIAL.CONATUS PHARMACEUTICALS INC - TO WORK WITH ITS PARTNER NOVARTIS ON ENSURING THAT ALL REMAINING OBLIGATIONS RELATED TO EMRICASAN PROGRAM ARE FULFILLED.CONATUS - RESULTS FROM 24-WEEK EXTENSION IN CO'S ENCORE-PH CLINICAL TRIAL OF EMRICASAN CONSISTENT WITH RESULTS FROM INITIAL 24-WEEK TREATMENT PERIOD.CONATUS PHARMACEUTICALS INC - RESULTS FROM 24-WEEK EXTENSION IN COMPANY'S ENCORE-PH CLINICAL TRIAL OF EMRICASAN DID NOT MEET PREDEFINED OBJECTIVES.

Bristol-Myers Squibb Is Planning Divestiture Of Otezla(Apremilast)

Monday, 24 Jun 2019

June 24 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB PROVIDES UPDATE ON PENDING MERGER WITH CELGENE.BRISTOL-MYERS SQUIBB CO - COMPANY IS PLANNING DIVESTITURE OF OTEZLA® (APREMILAST)..BRISTOL-MYERS SQUIBB CO - DIVESTITURE IS SUBJECT TO FURTHER REVIEW BY FTC AND REQUIRES THAT BRISTOL-MYERS SQUIBB ENTER INTO A CONSENT DECREE WITH FTC.BRISTOL-MYERS - REMAINS ACTIVELY ENGAGED IN DISCUSSIONS WITH U.S. FTC ON FTC'S CONTINUED REVIEW OF PROPOSED CELGENE TRANSACTION.BRISTOL-MYERS SQUIBB CO - CELGENE TRANSACTION CLOSING DATE CURRENTLY EXPECTED TO BE AT END OF 2019 OR BEGINNING OF 2020..BRISTOL-MYERS SQUIBB CO - PROCEEDS OF OTEZLA SALE WILL ALLOW BRISTOL-MYERS SQUIBB TO ACCELERATE ITS POST-CLOSING DELEVERAGING PLANS.BRISTOL-MYERS SQUIBB CO - BRISTOL-MYERS SQUIBB AND CELGENE HAVE CONCLUDED THEIR PRE-NOTIFICATION PROCESS WITH EUROPEAN COMMISSION.BRISTOL-MYERS SQUIBB CO - FOR CELGENE DEAL, SUBMITTED FORMAL APPLICATION FOR CLEARANCE BY EUROPEAN COMMISSION.

Perrigo Issues Voluntary Recall For Parent's Choice Advantage Infant Formula Milk-Based Powder With Iron

Friday, 21 Jun 2019

Perrigo Company PLC ::PERRIGO ISSUES VOLUNTARY RECALL FOR PARENT'S CHOICE ADVANTAGE INFANT FORMULA MILK-BASED POWDER WITH IRON.PERRIGO - ISSUING VOLUNTARY NATIONWIDE RECALL OF 35-OUNCE, 992-GRAM CONTAINERS OF PARENT'S CHOICE ADVANTAGE INFANT FORMULA MILK-BASED POWDER WITH IRON.PERRIGO COMPANY - THE RECALL IS BEING CONDUCTED IN CONSULTATION WITH U.S. FOOD AND DRUG ADMINISTRATION (FDA).PERRIGO COMPANY PLC - PARENT'S CHOICE ADVANTAGE INFANT FORMULA MILK-BASED POWDER WITH IRON PRODUCT IS SOLD EXCLUSIVELY AT WALMART.PERRIGO - PARENT'S CHOICE ADVANTAGE INFANT FORMULA MILK-BASED POWDER WITH IRON BEING RECALLED DUE TO POTENTIAL PRESENCE OF METAL FOREIGN MATTER.PERRIGO - PARENT'S CHOICE ADVANTAGE INFANT FORMULA MILK-BASED POWDER RECALL IS OUT OF AN ABUNDANCE OF CAUTION STEMMING FROM A CONSUMER REPORT.PERRIGO COMPANY - TOTAL NUMBER OF CONTAINERS OF PARENT'S CHOICE ADVANTAGE INFANT FORMULA MILK-BASED POWDER WITH IRON AFFECTED BY RECALL IS 23,388.

Biomarin Earns Milestone Payments From Pfizer

Friday, 21 Jun 2019

June 21 (Reuters) - Biomarin Pharmaceutical Inc ::BIOMARIN EARNS MILESTONE PAYMENTS FROM PFIZER FOR TALZENNA® (TALAZOPARIB) FOR METASTATIC BREAST CANCER PATIENTS WITH AN INHERITED BRCA MUTATION.BIOMARIN PHARMACEUTICAL INC - EUROPEAN COMMISSION APPROVAL TRIGGERS $15 MILLION PAYMENT.BIOMARIN PHARMACEUTICAL INC - BIOMARIN ENTITLED TO EARN MID-SINGLE DIGIT ROYALTIES ON FUTURE SALES.BIOMARIN PHARMACEUTICAL INC - COMPANY EARNED A $15 MILLION MILESTONE PAYMENT FROM PFIZER.BIOMARIN PHARMACEUTICAL INC - $15 MILLION MILESTONE PAYMENT WAS TRIGGERED BY EUROPEAN COMMISSION APPROVAL OF TALZENNA.

Biomarin Earns Milestone Payments From Pfizer

Friday, 21 Jun 2019

June 21 (Reuters) - Biomarin Pharmaceutical Inc ::BIOMARIN EARNS MILESTONE PAYMENTS FROM PFIZER FOR TALZENNA® (TALAZOPARIB) FOR METASTATIC BREAST CANCER PATIENTS WITH AN INHERITED BRCA MUTATION.BIOMARIN PHARMACEUTICAL INC - EUROPEAN COMMISSION APPROVAL TRIGGERS $15 MILLION PAYMENT.BIOMARIN PHARMACEUTICAL INC - BIOMARIN ENTITLED TO EARN MID-SINGLE DIGIT ROYALTIES ON FUTURE SALES.BIOMARIN PHARMACEUTICAL INC - COMPANY EARNED A $15 MILLION MILESTONE PAYMENT FROM PFIZER.BIOMARIN PHARMACEUTICAL INC - $15 MILLION MILESTONE PAYMENT WAS TRIGGERED BY EUROPEAN COMMISSION APPROVAL OF TALZENNA.

Richter, Allergan extend Cariprazine agreement to Latin America

Friday, 21 Jun 2019

June 21 (Reuters) - Richter Gedeon Vegyeszeti Gyar Nyrt GDRB.BU::.

Merck Hosts 2019 Investor Day Outlining Business Momentum, Strong Expected Growth And Focus On Innovative Research And Development

Thursday, 20 Jun 2019

June 20 (Reuters) - Merck & Co Inc ::MERCK HOSTS 2019 INVESTOR DAY OUTLINING BUSINESS MOMENTUM, STRONG EXPECTED GROWTH AND FOCUS ON INNOVATIVE RESEARCH AND DEVELOPMENT.MERCK & CO INC - "MOMENTUM ACROSS KEY PILLARS EXPECTED TO DRIVE STRONG REVENUE GROWTH EVERY YEAR OVER NEXT FIVE YEARS, INCLUDING 2023".MERCK & CO INC - MEANINGFUL OPERATING MARGIN EXPANSION EXPECTED.MERCK & CO INC - "MERCK WILL CONTINUE TO EVOLVE ITS OPERATING MODEL TO BUILD A LEANER, MORE EFFICIENT ORGANIZATION.".

Botanix Pharmaceuticals Says Proof Of Concept For BTX 1801 Efficacy Shown In Animal Wound Infection Model

Thursday, 20 Jun 2019

June 20 (Reuters) - Botanix Pharmaceuticals Ltd ::PROOF OF CONCEPT FOR BTX 1801 EFFICACY DEMONSTRATED IN AN ANIMAL WOUND INFECTION MODEL.

Markets

  • Sectors
  • Europe
  • U.S.
  • Asia

Sector Summary